Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02054455
Other study ID # PPI-SIBO-01
Secondary ID
Status Completed
Phase Phase 4
First received April 11, 2012
Last updated February 3, 2014
Start date November 2012
Est. completion date November 2013

Study information

Verified date February 2014
Source Federico II University
Contact n/a
Is FDA regulated No
Health authority Italy: Ethics Committee
Study type Interventional

Clinical Trial Summary

The aim of the study is to evaluate the potential protective effect of Lactobacillus paracasei subspecies paracasei F19 administration on bowel symptom onset in patients with gastro-esophageal reflux disease at long-term PPI treatment.


Description:

Population and study design

After the approval of the Local Ethical Committee and informed consent of patients, we will consecutively enrol, according to the calculated power of the study, 80 outpatients, among those referred to the Institutional centers on account of recent onset of typical reflux symptoms (heartburn and regurgitation).

Exclusion criteria will be: age <18 or >70 yrs; pregnancy or breast-feeding; evidence of major concomitant diseases (i.e., tumors, cardiovascular disorders and hepatic and/or renal failure); use of PPIs or H2-antagonists, non-steroidal anti-inflammatory drugs (NSAIDs) or antibiotics in the previous 3 months; presence of Helicobacter pylori (H. pylori) infection; erosive esophagitis; presence of bowel symptoms such as bloating, flatulence, abdominal pain, diarrhea and constipation in the last 6 months or irritable bowel syndrome (IBS) according to Rome III criteria.

All patients will undergo upper endoscopy. Patients who will fulfill the entry criteria will be enrolled in the study.

These patients will be treated with pantoprazole 40 mg die for 6 months and they will be randomly assigned to 4 arms:

- the first arm will receive placebo for 3 days/week for 6 months;

- the second arm will receive LP-F19 in a dose of 25x109 live bacterial cells for 3 days/week for 6 months;

- the third arm will receive LP-F19 in a dose of 25x109 live bacterial cells for 3 days/week for the first three months and placebo 3 days/week for the following three months;

- the fourth arm will receive placebo 3 days/week for the first three months and LP-F19 in a dose of 25x109 live bacterial cells for 3 days/week for the following three months.

Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.

Adherence to treatment Will be evaluated based on self-reporting by the patients and count of returned sackets during monthly control visits. Patients who will take at least 90% of the drugs (pantoprazole, LP-F19 and placebo) for at least 90% of the scheduled time will be considered compliant.

Before starting therapy (i.e. baseline evaluation) and every 4 weeks, each patient will fill up a structured questionnaire for symptom assessment, concerning heartburn and regurgitation, as well as, bowel symptoms, including bloating, abdominal pain, flatulence and bowel habit.

Symptom and bowel habit assessment

Baseline and every 4 weeks after the beginning of the therapy, each patient will fill up a structured questionnaire, focusing on the presence of heartburn, regurgitation, bloating, flatulence, abdominal pain, diarrhea and constipation, with the help of a physician interviewer. The questionnaire, according to a Likert scale, will assess frequency (0 = never, 1 = < 1 episode/week; 2 = < 3 episodes/week; 3 = > 3 episodes/week; 4 = daily episodes) and severity (0 = absent, 1 = mild i.e. not interfering with the daily activities, 2 = moderate i.e. limiting the daily activities, and 3 = severe i.e. hampering the daily activities) of each symptom during the previous 6 months, at baseline and during the last month at every 4-week checkpoints. According to an arbitrary index, symptoms will be considered significant when interfering with daily activities (i.e., mean total score, frequency plus severity, ≥ 4).

Subjects will record their bowel habit on validated diary cards, including every single stool and stool consistency. Stool consistency will be defined according to the Bristol Stool Form Scale (BSFS). Diary cards will be returned every four weeks.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date November 2013
Est. primary completion date November 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- recent onset of typical reflux symptoms (heartburn and regurgitation).

Exclusion Criteria:

- age <18 or >70 yrs

- pregnancy or breast-feeding

- evidence of major concomitant diseases (i.e., tumors, cardiovascular disorders and hepatic and/or renal failure)

- use of PPIs or H2-antagonists, non-steroidal anti-inflammatory drugs (NSAIDs) or antibiotics in the previous 3 months

- presence of Helicobacter pylori (H. pylori) infection

- erosive esophagitis

- presence of bowel symptoms such as bloating, flatulence, abdominal pain, diarrhea and constipation in the last 6 months or irritable bowel syndrome (IBS) according to Rome III criteria.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Intervention

Dietary Supplement:
Lactobacillus paracasei F19
25x10E9 live bacterial cells for 3 days/week for 6 months
Placebo
Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.

Locations

Country Name City State
Italy University Federico Ii Naples

Sponsors (3)

Lead Sponsor Collaborator
Federico II University Ospedale Nuovo Regina Margherita di Roma Dr. Salvatore Campo, University of Cantanzaro

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gastrointestinal symptom's assessment The questionnaire used to assess symptoms was built-up according to a four-point Likert scale evaluating both frequency (0 = never, 1 = < 1 episode/week; 2 = < 3 episodes/week; 3 = > 3 episodes/week; 4 = daily episodes) and severity (0 = absent, 1 = mild i.e. not interfering with the daily activities, 2 = moderate i.e. limiting the daily activities, and 3 = severe i.e. hampering the daily activities) of each symptom during the previous 6 months, at baseline and during the last month at every 4-week checkpoints. According to an arbitrary index, symptoms were considered significant when interfering with daily activities (i.e., mean total score, frequency plus severity, >4). up to 6 months No
Secondary Bowel habit assessment Subjects will record their bowel habits on validated diary cards, including every single stool and stool consistency. Stool consistency will be de?ned according to the Bristol Stool Form Scale (BSFS). Diary cards will be returned every four weeks. up to 6 months No
See also
  Status Clinical Trial Phase
Completed NCT05831527 - An Exploratory Investigation of a Supplement to Promote Gut Health N/A
Completed NCT03659747 - Effect of Probiotic Supplementation on Lactose Maldigestion Induced by Fat-free Milk N/A
Recruiting NCT05972291 - Mechanisms of Gulf War Illness N/A
Completed NCT03959722 - The Effect of Probiotics on GI Symptoms N/A
Recruiting NCT03514784 - Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder Phase 1/Phase 2
Completed NCT01927900 - The Effects Of HMO On The Faecal Microbiota And On Gastrointestinal Symptoms In Healthy Volunteers N/A
Recruiting NCT04919265 - Mother-Infant Cohort Study in Malaysia and China
Completed NCT01171014 - Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms Phase 2/Phase 3
Completed NCT00574197 - Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients Phase 4
Recruiting NCT03403387 - Effects of GlutenShield, a Prebiotic, Probiotic, and Enzyme Supplement, on the Gut Microbiome of Adults With GI Symptoms N/A
Completed NCT01964599 - Potato Fiber and Gastrointestinal Function: Phase 3 N/A
Recruiting NCT06248177 - Probiotic Effect on Gastrointestinal Symptoms (FLORABIOTIC REFUERZO). N/A
Withdrawn NCT04228003 - Pendulum D2D Glucose Control for Adults With Type 2 Diabetes N/A
Recruiting NCT06425094 - Effects of a Microalgae Extract Dietary Supplement on Gut Health, Anxiety, and Immune Function Phase 1
Completed NCT03714464 - Effect of Physical Form of Apples on Gastrointestinal Function and Satiety: a MRI Study N/A
Active, not recruiting NCT03696953 - The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization. Phase 2
Completed NCT02277431 - Probiotic Supplementation Among Adults With Recurrent Gastrointestinal Symptoms Phase 2/Phase 3
Completed NCT00677378 - Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain N/A
Completed NCT03685552 - Safety Evaluation of a Diet and Nutritional Supplementation Program- Purify 2.0 N/A
Completed NCT01184456 - A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System Phase 2